New York, Feb 20, 2026, 05:10 EST — Premarket
GRAIL Inc shares tumbled in U.S. premarket action Friday, slumping 47.6% to $53.20 after the cancer test developer posted mixed top-line numbers from its key NHS-Galleri study. The stock, listed on Nasdaq, had previously settled at $101.53. 1
Why does this reaction matter? The Galleri blood test anchors Grail’s commercial ambitions, and investors have been eyeing the NHS-Galleri data closely—it’s among the few big, randomized sets they’ve been waiting to see. A decisive win might have bolstered Grail’s case with physicians, insurers, and regulators. Missing the primary endpoint, though, usually puts the focus right back on the timeline.
Galleri’s list price in the U.S. sits near $1,000, though the test hasn’t received FDA approval, according to STAT News. As a result, both adoption and insurance coverage depend on the strength of trial data—and on whether payers trust what was demonstrated, and what wasn’t. 2
Grail said the NHS-Galleri trial—conducted across England’s National Health Service and enrolling roughly 142,000 people between 50 and 77 years old—missed its main goal: a statistically significant reduction in the combined rate of Stage III and Stage IV cancers. Despite that, the company highlighted a more than 20% drop in Stage IV diagnoses in the second and third screening rounds for a set of 12 particularly deadly cancers, when Galleri was added to standard screening. The trial also posted a four-fold jump in overall cancer detection compared to standard screening alone. No serious safety issues turned up, according to Grail, which now plans to track participants for another 6 to 12 months. “The difference is between Stage III and Stage IV disease,” said Professor Charles Swanton, one of the study’s lead investigators. 3
Further information could be a ways off. The company intends to send in its results for the 2026 American Society of Clinical Oncology annual meeting, set for May 29-June 2 in Chicago. 4
Grail posted a 14% jump in fourth-quarter revenue, hitting $43.6 million, with net loss for the period tightening to $99.2 million. Revenue for the full year reached $147.2 million; net loss tallied $408.4 million. By the end of 2025, the company was sitting on $904.4 million in cash, cash equivalents and short-term marketable securities. “2025 was a year of significant commercial growth for GRAIL,” CEO Bob Ragusa said. In January, Grail wrapped up its final modular submission for a premarket approval application to the FDA. 5
The company’s going after U.S. clearance for Galleri through premarket approval, or PMA. Investors are hunting for signals on how regulators might react to a trial that didn’t hit its primary endpoint, but did report fewer metastatic, Stage IV cancers — the toughest cases.
There’s a clear downside scenario here. A primary miss lets skeptics claim that earlier detection still hasn’t shown a real impact on lowering advanced disease across the broader population. Payers have more reason to hold back, and the company keeps pouring money into stoking demand and tracking longer-term outcomes.
The implications stretch past Grail. Blood-based cancer screening remains a tightly packed, scrutinized area in diagnostics—so a misstep in one of the largest trials tends to dampen enthusiasm for the wider push into “multi-cancer early detection.”
Analysts were already divided ahead of the readout. TD Cowen started coverage on Grail back on Feb. 19, giving the stock a Hold and setting a $114 target, MT Newswires reported. 6
Traders are watching to see if the drop sticks once the market opens at 9:30 a.m. EST. Investors with a longer view are still focused on two key timelines: the FDA review period, and the full NHS-Galleri dataset the company aims to present at ASCO in late May.
